Abstract 1506TiP
Background
Osimertinib (osi) is the current first-line standard treatment for patients with NSCLCs with EGFR 19/21. Data suggest that combining EGFR tyrosine kinase inhibitor (TKI) with chemotherapy may be superior to a sequential approach of first-line TKI followed by salvage therapy. AMI is an EGFR/MET bi-specific antibody currently approved for NSCLCs with EGFR exon 20 insertions, but which is also being evaluated for NSCLCs with EGFR 19/21 in combination with chemotherapy (MARIPOSA-2 study) after osi progression. We designed AMIGO-1 to test the primary hypothesis that, in the first-line setting, the triplet regimen of AMI, combined with the 3rd generation irreversible TKI L, and P will improve progression-free survival (PFS) compared to historical controls, with an acceptable safety profile.
Trial design
AMIGO 1 is a single-arm, phase 2, multicenter trial, conducted through LACOG. Eligibility criteria include treatment-naïve, PS 0–1 patients with advanced NSCLCs with EGFR 19/21. Patients receive L 240mg PO daily, plus 21-day cycles of P 500mg/m2 IV on Day 1, plus A: 1400mg IV (1750mg if body weight >=80Kg) once weekly in cycle 1; 1400mg IV (1750mg if body weight >=80Kg) on Day 1 in cycle 2; 1750mg IV (2100mg if body weight >=80Kg) at Day 1 from cycle 3 onwards. The primary endpoint is 18-month PFS (18m-PFS), estimated by the Kaplan-Meier method. A one group chi-square test with a type I error of 0.1 (one-sided) will have 80% power to detect the difference between the null hypothesis (18m-PFS of 50%, achieved with osi alone) and the alternative hypothesis (18m-PFS of 65%) with a sample size of 49. AMIGO-1 trial was opened to recruitment in May 2023 in research centers in Brazil. Clinical trial information: NCT05299125. This trial in progress is the first to assess the triplet regimen of lazertinib, amivantamab, and pemetrexed as first-line treatment for (NSCLCs) with EGFR mutations and will provide benchmark results to be contrasted with the present standard of care and future treatment combinations that are currently undergoing evaluation in phase 3 trials (eg. FLAURA2, MARIPOSA).
Clinical trial identification
NCT05299125.
Editorial acknowledgement
Legal entity responsible for the study
Latin American Cooperative Oncology Group (LACOG).
Funding
Janssen.
Disclosure
W. Nassib William Junior: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, BMS, Eli Lilly, Merck, Roche/Genentech, Boehringer Ingelheim, Pfizer, Bayer, Sanofi, Takeda, Novartis, Libbs, Janssen. G. De Castro Jr.: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Libbs, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA, Yuhan; Financial Interests, Local PI: Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Roche; Financial Interests, Steering Committee Member: AstraZeneca, Bayer, BeiGene, Merck Sharp & Dohme; Financial Interests, Personal, Steering Committee Member: GSK, Novartis; Financial Interests, Institutional, Local PI: Lilly, Pfizer, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21